- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07588282
The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intentions Among Patients With Functional Neurological Movement Disorders
The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intentions in Patients With Functional Neurological Movement Disorders: An Intervention Study Using a Within-Subject Design
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Functional neurological disorders (FNDs) are common neurological conditions associated with a significant reduction in quality of life and a poor prognosis if diagnosis is delayed. FNDs have multifactorial causes, including psychological stressors, psychiatric comorbidities, and past trauma. A characteristic feature of FNDs is their susceptibility to influence by attention: symptoms can be intensified by increased focus and alleviated by distraction. Despite the establishment of positive diagnostic criteria that position FNS as disorders to be actively diagnosed rather than merely excluded, communicating this in clinical practice remains a challenge. There is often a lack of clear, empathetic, and patient-centered communication of the diagnosis by physicians. Previous studies have shown that the way in which a diagnosis of functional disorders is communicated can have a decisive influence on understanding of the condition, acceptance of the diagnosis, willingness to undergo treatment, and long-term outcomes. In particular, psychoeducational intervention studies show positive effects; however, these have so far been investigated primarily within the context of complex group programs, which are potentially biased by participant self-selection. It remains unclear whether structured, empathetic, and guideline-based individual counseling provided during a regular doctor-patient consultation can achieve similar positive effects. In addition, many physicians report feeling uncertain about how to interact with patients with unexplained symptoms, which can negatively impact the quality of physician- patient communication and the physician-patient relationship. Patients are often simply told which other diseases have been ruled out, without receiving a comprehensible explanation for their symptoms-which can encourage repeated visits to other doctors ("doctor shopping"). Despite the recommendation for patient-centered, understandable, and empathetic explanation of the FNS diagnosis as the first step in treatment, there has been a lack of systematic research to date on the specific effectiveness of this explanation in the doctor-patient conversation. Against this backdrop, the planned study aims to investigate the impact of an empathetic, psychoeducational explanation of the diagnosis on patients newly diagnosed with a functional movement disorder (FMD). The focus is on changes in the perception of the condition and in symptom severity and burden, as well as confidence in the diagnosis of the functional movement disorder, the patients' communication experience and satisfaction with the physician who conveys the diagnosis, intentions regarding "doctor shopping," as well as remaining unanswered questions, individual preferences, and support needs following the diagnosis.
In addition, the self-efficacy of physicians in communicating the diagnosis will be assessed to identify potential correlations with patients' confidence in the diagnosis and the positive effect of the intervention on other variables.
As part of the study, magnetic resonance imaging (MRI) will also be used once as a supplementary imaging modality to assess anatomical and functional aspects of the brain and to make comparisons between participants who show improvements in symptoms and quality of life over the course of the study and those who do not, as well as with healthy control groups.
Study Design: The study follows a prospective intervention design with repeated measurements at four time points within the same participants (within-subject waitlist design). Following an initial baseline assessment (T0), all participants undergo a four-week waiting period without intervention, which serves as an intra-individual control condition.
The measurement time points following the baseline assessment (T0) occur before the diagnosis is made (T1), immediately afterward (T2), four weeks later (T3), and three months later (T4). A separate control group of individuals who do not receive an intervention is not included.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Maria Schneller
- Numéro de téléphone: 004331638580395
- E-mail: maria.schneller@medunigraz.at
Lieux d'étude
-
-
-
Graz, L'Autriche, 8036
- Recrutement
- Medical University of Graz
-
Contact:
- Maria Schneller, Master of Science
- Numéro de téléphone: 0043/316/385/833 79
- E-mail: maria.schneller@medunigraz.at
-
Contact:
- Petra Schwingenschuh, Professor
- Numéro de téléphone: 004331638583379
- E-mail: petra.schwingenschuh@medunigraz.at
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Presence of any of the following functional movement disorders:
- Functional paralysis
- Functional seizures
- Functional tremor
- Functional drop attacks
- Functional dystonia
- Functional twitching
- Functional facial symptoms
- Functional tics
- Functional parkinsonism
Exclusion Criteria:
- The patient is unable to give informed consent.
- The patient is temporarily unable to give informed consent.
- The patient does not have sufficiently understand German language to answer the questionnaires (the questionnaires are available only in German).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Standardized FND Psychoeducation Guideline
|
The intervention is a structured communication protocol used by physicians to provide a systematic, evidence-based explanation of the diagnosis to patients with Functional Movement Disorders (FMD).
The primary goal is to foster a common understanding of the condition, validate the patient's experience, and establish a foundation for active rehabilitation.
The psychoeducational session follows a 14-step framework designed to address the clinical, neurological, and psychological dimensions of the disorder
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Illness Perception
Délai: 4 months (at each measurement point)
|
Revised Illness Perception Questionnaire (IPQ-R), Range (min, max scores) varies by subscale (typically 1-5 per item), Higher scores indicate more negative perceptions.
|
4 months (at each measurement point)
|
|
Trust in the diagnosis
Délai: From immediately post-intervention to the last follow up
|
3 questions whether participants trust the diagnosis
|
From immediately post-intervention to the last follow up
|
|
Doctor shopping intentions
Délai: From post-intervention to the last follow up
|
Question on whether participants intent to consult other physicians regarding their diagnosis in the future
|
From post-intervention to the last follow up
|
|
Symptom Burden of functional movement disorders
Délai: at baseline and the pre-intervention
|
Symptom-Functional Movement Disorder Rating Scale (S-FMDRS), Range: 0 - 60; higher scores mean greater symptom burden and severity
|
at baseline and the pre-intervention
|
|
Patient Global Impression of Severity / Change (PGI-S/C)
Délai: At baseline (severity), before the intervention (change), at the first follow up and at the second follow up)
|
standardized instrument to assess the subjective impression of disease severity and change with 3 items, rated on a likert scale from 1-5.
Range of the full scale: 3-15 (higher values indicate higher severity of the disease)
|
At baseline (severity), before the intervention (change), at the first follow up and at the second follow up)
|
|
Clinician Global Impression of Severity / Change (CGI-S/C)
Délai: At baseline (severity), before the intervention (change), at the first follow up and at the second follow up)
|
standardized instrument for clinicians to assess the clinicians' impression of disease severity and change of the patient, with 3 items, rated on a likert scale from 1-5.
Range of the full scale: 3-15 (higher values indicate higher severity of the disease)
|
At baseline (severity), before the intervention (change), at the first follow up and at the second follow up)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Functional comorbidities
Délai: at baseline
|
measured with selected subscales of the PHQ-D , which is the German translation and validation of the "Patient Health Questionnaire (PHQ)" by Löwe et al., 1999.
Higher values indicate higher scores indicate more severe symptoms of depression, anxiety, or somatization.
Scores range from 0-3 per item.
|
at baseline
|
|
Patient-reported outcome measures of functional neurological disorders
Délai: at baseline, pre-intervention, 1st and 2nd follow up
|
PROM questionnaire by Michaelis et al. (2026) assessing the extent and the impact of the movement disorder on the patient.
Self-reported measurement.
Range: 16 to 80 with higher values indicating higher severity/impairment.
|
at baseline, pre-intervention, 1st and 2nd follow up
|
|
health-related quality of life
Délai: baseline, pre-intervention and at the 1st follow up
|
Assessed with the Short Form 36 Health Survey (SF36), a questionnaire of the patient's subjective quality of life, measured with 36 items rated on a likert scale, range of the total score goes from 0 to 100 with higher values indicating better health-related quality of life and function.
|
baseline, pre-intervention and at the 1st follow up
|
|
Remaining questions
Délai: immediately after the intervention and at the first follow up
|
assessing remaining open questions with regards to the FND diagnosis after the psychoeducation and diagnosis explanation , asked by the study team
|
immediately after the intervention and at the first follow up
|
|
Patient preferences
Délai: immediately after the intervention and at the first follow up
|
Assessing patients treatment preferences, practical, social and systematic support preferences with regards to the FND diagnosis asked through open questions by the study team
|
immediately after the intervention and at the first follow up
|
|
Communication quality
Délai: immediately post-intervention.
|
Assess the patient's rating of the communication quality with the clinician, assessed with the standardized EORTC-QLQ-COMU26-questionnaire (translated and validated german version) Range: 0-100, high score indicates good communication.
|
immediately post-intervention.
|
|
Substance Addiction
Délai: at baseline
|
WHO - ASSIST V3.0 (Alcohol, Smoking & Substance Involvement Screening Test), scores are evaluated for each substance separetely with higher values indicating higher risk for addiction.
Range from 0 to 27+ for high risk level.
|
at baseline
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1392/2025
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .